RAPT Therapeutics (RAPT) to Release Quarterly Earnings on Thursday

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.69). On average, analysts expect RAPT Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

RAPT Therapeutics Stock Down 2.5 %

Shares of RAPT traded down $0.02 during mid-day trading on Monday, hitting $0.94. 567,386 shares of the company's stock were exchanged, compared to its average volume of 860,678. RAPT Therapeutics has a 52 week low of $0.75 and a 52 week high of $8.44. The stock's 50-day simple moving average is $1.06 and its 200-day simple moving average is $1.28. The firm has a market cap of $124.48 million, a price-to-earnings ratio of -0.34 and a beta of -0.04.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of RAPT Therapeutics in a research report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $4.00.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.